OmniAb, Inc. (OABI)

Market Cap	393.74M
Revenue (ttm)	51.57M
Net Income (ttm)	-43.60M
Shares Out	115.13M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	854,001
Open	3.45
Previous Close	3.43
Day's Range	3.35 - 3.49
52-Week Range	1.91 - 10.50
Beta	n/a
Analysts	Buy
Price Target	10.54 (+208.19%)
Earnings Date	Mar 30, 2023

About OABI

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therap...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: OABI

Financial Performance

In 2021, OmniAb's revenue was $34.75 million, an increase of 49.34% compared to the previous year's $23.27 million. Losses were -$27.04 million, 54.0% more than in 2020.

Analyst Forecast

According to 12 analysts, the average rating for OABI stock is "Buy." The 12-month stock price forecast is $10.54, which is an increase of 208.19% from the latest price.

Price Target

$10.54

(208.19% upside)

Analyst Consensus: Buy